LifeWatch AG
LifeWatch AG: BioTelemetry publishes the definitive notice of the interim result
LifeWatch AG / Key word(s): Offer BioTelemetry publishes the definitive notice of the interim result ZUG, Switzerland, June 14, 2017 – With the definitive interim result now available, BioTelemetry (the Offeror) confirmed today that the shareholders tendered approximately 83 percent of the outstanding total shares of Lifewatch AG during the tender period and declared the offer to be successful, subject to the satisfaction of certain offer conditions. Including the LifeWatch shares tendered into the offer, the participation of the Offeror and the persons acting in concert with the Offeror at the end of the offer period on June 8, 2017, 4.00 p.m. CET, is 15,425,499 LifeWatch shares in total. This corresponds to 83 percent of the voting rights and the share capital of LifeWatch. The additional acceptance period of 10 trading days for the subsequent acceptance of the offer will start on June 15, 2017, and is expected to run until June 28, 2017, 4.00 p.m. CET. Subject to the satisfaction of all conditions in accordance with the offer prospectus, settlement of the offer is expected to take place on July 13, 2017.
About LifeWatch AG About BioTelemetry Cautionary Statement Regarding Forward-Looking Statements BioTelemetry and any of its subsidiaries and any advisor, broker or financial institution acting as an agent or for the account or benefit of BioTelemetry or the Offeror may, subject to applicable Swiss securities laws, rules and regulations, make certain purchases of, or arrangements to purchase, LifeWatch shares from shareholders of LifeWatch who are willing to sell their LifeWatch shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices. The Offeror will disclose promptly any information regarding such purchases of LifeWatch shares in Switzerland through the electronic media and/or the stock exchange and in the U.S. by means of a press release, if and to the extent required under applicable laws, rules and regulations in Switzerland. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. federal securities laws, since LifeWatch is located in a non-U.S. jurisdiction, and some or all of its officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court’s judgment. The receipt of cash and stock consideration in the Offer by a U.S. shareholder will generally be a taxable transaction for U.S. federal, state and local income tax purposes. Each U.S. shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of acceptance of the Offer. Securities may not be offered or sold in the U.S. absent registration or an exemption from registration under the U.S. Securities Act. It is expected that the Offer will be subject to a Tier I exemption pursuant to Rule 14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that the issuance of BioTelemetry Common Stock in connection therewith will be exempt from registration under the U.S. Securities Act of 1933, as amended, pursuant to Rule 802 thereof. Neither the Securities and Exchange Commission nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the pre-announcement. Any representation to the contrary is a criminal offense in the U.S. Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=CXEXAXWXJO Document title: LifeWatch AG: BioTelemetry publishes the definitive notice of the interim result End of ad hoc announcement |
Language: | English |
Company: | LifeWatch AG |
Baarerstrasse 139 | |
6300 Zug | |
Switzerland | |
Phone: | +41 41 728 67 78 |
Internet: | www.lifewatch.com |
ISIN: | CH0012815459 |
Valor: | 811189 |
Listed: | Regulated Unofficial Market in Berlin, Stuttgart; Open Market in Frankfurt; SIX Swiss Exchange |
End of Announcement | EQS Group News Service |